Corbus Concludes Phase II study of Cystic Fibrosis Candidate
Corbus Pharmaceuticals Holdings, Inc. CRBP , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF). Read more >>